In addition, BCL2A1 was a critical mediator of B‐cell survive and regulated by Spleen tyrosine kinase and Bruton tyrosine kinase, and was associated with advancement of hematological malignancies as well as solid tumor (Sochalska et al., 2016; Vogler, 2012). Here, BCL2A1 is linked to hematologic disorder.